Zobrazeno 1 - 10
of 109
pro vyhledávání: '"Guy L. Odom"'
Autor:
Marcelo dos Santos Voltani Lorena, Estela Kato dos Santos, Renato Ferretti, G. A. Nagana Gowda, Guy L. Odom, Jeffrey S. Chamberlain, Cintia Yuri Matsumura
Publikováno v:
Skeletal Muscle, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Background Duchenne muscular dystrophy (DMD) is a severe form of muscular dystrophy without an effective treatment, caused by mutations in the DMD gene, leading to the absence of dystrophin. DMD results in muscle weakness, loss of ambulation
Externí odkaz:
https://doaj.org/article/bee194a80f0f4dbb94252899775bccf4
Autor:
Arden B. Piepho, Jeovanna Lowe, Laurel R. Cumby, Lisa E. Dorn, Dana M. Lake, Neha Rastogi, Megan D. Gertzen, Sarah L. Sturgill, Guy L. Odom, Mark T. Ziolo, Federica Accornero, Jeffrey S. Chamberlain, Jill A. Rafael-Fortney
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 28, Iss , Pp 344-354 (2023)
Micro-dystrophin gene replacement therapies for Duchenne muscular dystrophy (DMD) are currently in clinical trials, but have not been thoroughly investigated for their efficacy on cardiomyopathy progression to heart failure. We previously validated F
Externí odkaz:
https://doaj.org/article/112376132c914e0588ee19091b2c6a91
Autor:
Stephen C. Kolwicz, Jr., PhD, John K. Hall, PhD, Farid Moussavi-Harami, MD, Xiolan Chen, PhD, Stephen D. Hauschka, PhD, Jeffrey S. Chamberlain, PhD, Michael Regnier, PhD, Guy L. Odom, PhD
Publikováno v:
JACC: Basic to Translational Science, Vol 4, Iss 7, Pp 778-791 (2019)
Summary: Mutations in the gene encoding for dystrophin leads to structural and functional deterioration of cardiomyocytes and is a hallmark of cardiomyopathy in Duchenne muscular dystrophy (DMD) patients. Administration of recombinant adeno-associate
Externí odkaz:
https://doaj.org/article/4212bb9493db490e828183607656df25
Autor:
Zachary M. Howard, Lisa E. Dorn, Jeovanna Lowe, Megan D. Gertzen, Pierce Ciccone, Neha Rastogi, Guy L. Odom, Federica Accornero, Jeffrey S. Chamberlain, Jill A. Rafael-Fortney
Publikováno v:
JCI Insight, Vol 6, Iss 7 (2021)
Gene replacement for Duchenne muscular dystrophy (DMD) with micro-dystrophins has entered clinical trials, but efficacy in preventing heart failure is unknown. Although most patients with DMD die from heart failure, cardiomyopathy is undetectable unt
Externí odkaz:
https://doaj.org/article/edf8afa3bfcf4133a3ecce62112683f8
Autor:
Niclas E. Bengtsson, John K. Hall, Guy L. Odom, Michael P. Phelps, Colin R. Andrus, R. David Hawkins, Stephen D. Hauschka, Joel R. Chamberlain, Jeffrey S. Chamberlain
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-10 (2017)
CRISPR/Cas9-mediated gene editing is an emerging strategy to treat Duchenne muscular dystrophy. Here the authors develop multiple CRISPR/Cas9-based approaches to correct different dystrophin gene mutations, and show significant restoration of dystrop
Externí odkaz:
https://doaj.org/article/42b84f4d2d7e485cb3c0f8f3e7eaf353
Autor:
Kassandra S. Thomson, PhD, Guy L. Odom, PhD, Charles E. Murry, MD, PhD, Gregory G. Mahairas, PhD, Farid Moussavi-Harami, MD, Sam L. Teichman, MD, Xiaolan Chen, PhD, Stephen D. Hauschka, PhD, Jeffrey S. Chamberlain, PhD, Michael Regnier, PhD
Publikováno v:
JACC: Basic to Translational Science, Vol 1, Iss 7, Pp 666-679 (2016)
Despite recent advances, chronic heart failure remains a significant and growing unmet medical need, reaching epidemic proportions carrying substantial morbidity, mortality, and costs. A safe and convenient therapeutic agent that produces sustained i
Externí odkaz:
https://doaj.org/article/d156eb416a674b9bb2f4b5a526ecf031
Autor:
Niclas E. Bengtsson, John K. Hall, Guy L. Odom, Michael P. Phelps, Colin R. Andrus, R. David Hawkins, Stephen D. Hauschka, Joel R. Chamberlain, Jeffrey S. Chamberlain
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-1 (2017)
Nature Communications 8: Article number: 14454 (2017); Published: 14 February 2017; Updated: 23 June 2017 This Article contains an error in Fig. 4, for which we apologize. In panel a, the image reporting dystrophin labelling following SaCas9Δ5253 tr
Externí odkaz:
https://doaj.org/article/77235027c66448b889ec5dc2c4163e56
Autor:
Ketaki N Mhatre, Julie Mathieu, Amy Martinson, Galina Flint, Leslie P. Blakley, Arash Tabesh, Hans Reinecke, Xiulan Yang, Xuan Guan, Eesha Murali, Jordan M Klaiman, Guy L Odom, Mary Beth Brown, Rong Tian, Stephen D Hauschka, Daniel Raftery, Farid Moussavi-Harami, Michael Regnier, Charles E Murry
Transplanted human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) improve ventricular performance when delivered acutely post-myocardial infarction but are ineffective in chronic myocardial infarction/heart failure. 2’-deoxy-ATP (dATP) act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e665b470ba9e0494d5530ab7fecca44b
https://doi.org/10.1101/2023.04.24.538108
https://doi.org/10.1101/2023.04.24.538108
Autor:
John K. Hall, Farid Moussavi-Harami, Stephen C. Kolwicz, Jeffrey S. Chamberlain, Stephen D. Hauschka, Xiolan Chen, Michael Regnier, Guy L. Odom
Publikováno v:
JACC: Basic to Translational Science, Vol 4, Iss 7, Pp 778-791 (2019)
JACC: Basic to Translational Science
JACC: Basic to Translational Science
Visual Abstract
Highlights • rAAV vectors increase cardiac-specific expression of RNR and elevate cardiomyocyte 2-dATP levels. • Elevated myocardial RNR and subsequent increase in 2-dATP rescues the performance of failing myocardium, an effe
Highlights • rAAV vectors increase cardiac-specific expression of RNR and elevate cardiomyocyte 2-dATP levels. • Elevated myocardial RNR and subsequent increase in 2-dATP rescues the performance of failing myocardium, an effe
Autor:
Neha Rastogi, Lisa E. Dorn, Megan D. Gertzen, Jeovanna Lowe, Zachary M. Howard, Guy L. Odom, Jill A. Rafael-Fortney, Jeffrey S. Chamberlain, Federica Accornero, Pierce C. Ciccone
Publikováno v:
JCI Insight, Vol 6, Iss 7 (2021)
JCI Insight
JCI Insight
Gene replacement for Duchenne muscular dystrophy (DMD) with micro-dystrophins has entered clinical trials, but efficacy in preventing heart failure is unknown. Although most patients with DMD die from heart failure, cardiomyopathy is undetectable unt